Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia [ID1083]
In development [GID-TA10260] Expected publication date: TBC
Search results
493 results
-
-
Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588
In development [GID-TA10507] Expected publication date: TBC
-
Selpercatinib for treating advanced thyroid cancer with RET alterations [ID3744]
In development [GID-TA10614] Expected publication date: 23 June 2021
-
Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]
In development [GID-TA10618] Expected publication date: 23 June 2021
-
Budesonide for treating active eosinophilic oesophagitis [ID1202]
In development [GID-TA10372] Expected publication date: 23 June 2021
-
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]
In development [GID-TA10615] Expected publication date: TBC
-
Breast cancer (brain metastases) - etirinotecan pegol [ID881]
In development [GID-TA10066] Expected publication date: TBC
-
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
In development [GID-TA10375] Expected publication date: TBC
-
Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]
In development [GID-TA10484] Expected publication date: TBC
-
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]
In development [GID-TA10370] Expected publication date: TBC
-
Baloxavir marboxil for treating influenza [ID1537]
In development [GID-TA10559] Expected publication date: TBC
-
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]
In development [GID-TA10544] Expected publication date: TBC
-
Apalutamide for treating prostate cancer [ID1534]
In development [GID-TA10423] Expected publication date: 26 May 2021
-
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]
In development [GID-TA10491] Expected publication date: TBC
-
Short bowel syndrome - teduglutide [ID885]
In development [GID-TA10048] Expected publication date: TBC
-
Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma [ID1625]
In development [GID-TA10643] Expected publication date: 16 June 2021
-
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
In development [GID-TA10667] Expected publication date: TBC
-
Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]
In development [GID-TA10534] Expected publication date: TBC
-
Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]
In development [GID-TA10524] Expected publication date: TBC
-
Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]
In development [GID-TA10697] Expected publication date: TBC
-
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development [GID-TA10592] Expected publication date: TBC
-
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
In development [GID-TA10596] Expected publication date: 15 December 2021
-
Amivantamab for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer after platinum-based chemotherapy [ID3836]
In development [GID-TA10729] Expected publication date: TBC
-
Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]
In development [GID-TA10701] Expected publication date: 20 July 2022
-
Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]
In development [GID-TA10669] Expected publication date: 04 May 2022
-
Non-bisphosphonates for treating osteoporosis [ID901]
In development [GID-TA10072] Expected publication date: TBC
-
Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617
In development [GID-TA10545] Expected publication date: 21 April 2021
-
Andexanet alfa for reversing anticoagulation [ID1101]
In development [GID-TA10440] Expected publication date: 14 April 2021
-
Fenfluramine for treating Dravet syndrome [ID1109]
In development [GID-TA10373] Expected publication date: 26 May 2021
-
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies [ID3805]
In development [GID-TA10671] Expected publication date: TBC
-
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]
In development [GID-TA10646] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
In development [GID-TA10405] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]
In development [GID-TA10531] Expected publication date: 15 December 2021
-
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]
In development [GID-TA10481] Expected publication date: 18 August 2021
-
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID3816]
In development [GID-TA10806] Expected publication date: TBC
-
Relugolix with oestradiol and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: 09 March 2022
-
Pembrolizumab for advanced, unresectable or metastatic urothelial cancer (CDF review of TA522) [ID1634]
In development [GID-TA10710] Expected publication date: TBC
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]
In development [GID-TA10708] Expected publication date: 22 December 2021
-
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)
In development [GID-TA10527] Expected publication date: TBC
-
Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]
In development [GID-TA10299] Expected publication date: TBC
-
Third molars (impacted) - prophylactic removal [ID898]
In development [GID-TAG525] Expected publication date: TBC
-
Multiple sclerosis - sativex [ID387]
In development [GID-TAG368] Expected publication date: TBC
-
Skin abscess: antimicrobial prescribing
In development [GID-NG10163] Expected publication date: TBC
-
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
In development [GID-TA10664] Expected publication date: TBC
-
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
In development [GID-TA10711] Expected publication date: 15 September 2021
-
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]
In development [GID-TA10558] Expected publication date: TBC
-
Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]
In development [GID-TA10470] Expected publication date: TBC
-
Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (Review of TA397) [ID1591]
In development [GID-TA10626] Expected publication date: 21 July 2021
-
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
In development [GID-TA10611] Expected publication date: TBC
-
Bulevirtide for treating chronic hepatitis D [ID3732]
In development [GID-TA10652] Expected publication date: 20 October 2021